Cell Contact–Dependent Priming and Fc Interaction with CD32+ Immune Cells Contribute to the TGN1412-Triggered Cytokine Response
The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Abstract
Following inconspicuous preclinical testing, the superagonistic anti-CD28 mAb TGN1412 was applied to six study participants who all developed a devastating cytokine storm. We verified that TGN1412 treatment of fresh PBMCs induced only moderate responses, whereas restoration of tissue-like conditions by high-density preculture (HDC) allowed vigorous cytokine production. TGN1412 treatment of T cells isolated from HDC-PBMCs induced moderate cytokine responses, which upon additional anti-IgG crosslinking were significantly boosted. Moreover, coincubation of TGN1412-treated T cells with B cells expressing the intermediate affinity Fcγ receptor IIB (CD32B), or coincubation with CD32B+ transfectants, resulted in robust T cell activation. This was surprising because TGN1412 was expressed as an Ig of the subclass 4 (IgG4), which was shown before to exhibit only minor affinity to FcγRs. Transcriptome analysis of TGN1412-treated T cells revealed that similar gene signatures were induced irrespective of whether T cells derived from fresh or HDC-PBMCs were studied. Collectively, these data indicate that HDC-PBMCs and HDC-PBMC–derived T cells mount rapid TGN1412 responses, which are massively boosted by FcγR crosslinking, in particular by CD32-expressing B cells. These results qualify HDC-PBMCs as a valuable in vitro test system for the analysis of complex mAb functions.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“One unexpected finding of post-London TGN1412 research, however, concerns the contribution of Fc receptor-mediated crosslinking to the stimulatory activity of TGN1412.”
From The rise and fall of the CD 28 superagonist TGN 1412 and its return as TAB 08: a personal account (2016) · cites this paper as [51]
In the citing paper
“even Fab2 fragments (which lack the Fc part of the antibody) are able to induce a cytokine response from CD4EM T-cells reset to tissue-like conditions, although this is less pronounced than with the intact antibody [51].”
From The rise and fall of the CD 28 superagonist TGN 1412 and its return as TAB 08: a personal account (2016) · cites this paper as [51]
In the citing paper
“its interaction with FcgammaRII (CD32B), an Fc receptor expressed on B cells, boosts its T cell-activating properties [51].”
From The rise and fall of the CD 28 superagonist TGN 1412 and its return as TAB 08: a personal account (2016) · cites this paper as [51]
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.
Langmead, B., Trapnell, C., Pop, M., & Salzberg, S. L. (2009) · Genome Biology · doi:10.1186/gb-2009-10-3-r25 · Cited by 21,849 · cited 1×
“Sequence reads were aligned to the human reference genome hg19 (23) using Bowtie (24), allowing two mismatches and retrieving best matches in case of ambiguous alignment.”
MethodDifferential expression analysis for sequence count data
Anders, S., & Huber, W. (2010) · Genome Biology · doi:10.1186/gb-2010-11-10-r106 · Cited by 15,581
Mapping and quantifying mammalian transcriptomes by RNA-Seq
Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L., & Wold, B. (2008) · Nature Methods · doi:10.1038/nmeth.1226 · Cited by 13,696 · cited 1×
“Read counts were normalized to reads per kilobase of exon model per million mapped reads (26).”
MethodFinishing the euchromatic sequence of the human genome
International Human Genome Sequencing Consortium (2004) · Nature · doi:10.1038/nature03001 · Cited by 4,971
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164
Bruhns, P., Iannascoli, B., England, P., Mancardi, D. A., Fernandez, N., Jorieux, S., & Daëron, M. (2009) · Blood · doi:10.1182/blood-2008-09-179754 · Cited by 1,479 · cited 2×
“These results were surprising because generally it was assumed that Abs of the IgG4k subclass, the format in which TGN1412 was engineered for the use in humans (6), would not show significant interaction with FcgR (29, 36–38), whereas few studies speculated that IgG4k may show some interaction with CD64 and very low i…”
BackgroundEvolutionary and biomedical insights from the rhesus macaque genome.
Gibbs, R. A., Rogers, J., Katze, M. G., Bumgarner, R., Weinstock, G. M., Mardis, E. R., Remington, K. A., Strausberg, R. L., Venter, J. C., Wilson, R. K., et al. (2007) · Science · doi:10.1126/science.1139247 · Cited by 1,403
The safety and side effects of monoclonal antibodies
Hansel, T. T., Kropshofer, H., Singer, T., Mitchell, J. A., & George, A. J. T. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3003 · Cited by 1,144 · cited 8×
“Although staining with different Abs does not allow comparison of levels of surface expression of different FcgRs, cytofluorometric analysis revealed that all recombinant receptors were expressed (33).”
BackgroundInfluentialMicroRNA-155 Promotes Autoimmune Inflammation by Enhancing Inflammatory T Cell Development
O'Connell, R. M., Kahn, D., Gibson, W. S. J., Round, J. L., Scholz, R. L., Chaudhuri, A. A., Kahn, M. E., Rao, D. S., & Baltimore, D. (2010) · Immunity · doi:10.1016/j.immuni.2010.09.009 · Cited by 889
Cited by
The promise and challenges of immune agonist antibody development in cancer
Mayes, P. A., Hance, K. W., & Hoos, A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.75 · Cited by 355
White, A. L., Chan, H. T. C., French, R. R., Willoughby, J., Mockridge, C. I., Roghanian, A., Penfold, C. A., Booth, S. G., Dodhy, A., Polak, M. E., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.001 · Cited by 173
“…is both unexpected and unexplained, as almost all agonistic mAbs described to date, including the anti-CD28 superagonist TGN1412, which caused catastrophic toxicity in healthy volunteers in 2006 (Suntharalingam et al., 2006), require FcgR crosslinking for activity (Bartholomaeus et al., 2014).”
FcγR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities
Nimmerjahn, F., Gordan, S., & Lux, A. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.04.005 · Cited by 172
Immune Checkpoints as Therapeutic Targets in Autoimmunity
Paluch, C., Santos, A. M., Anzilotti, C., Cornall, R. J., & Davis, S. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02306 · Cited by 140
“The superagonistic activity of the antibody TGN1412 which targeted the costimulatory receptor CD28 was found to depend on binding to FcγRIIB in vitro (75).”
BackgroundFc-engineered antibodies with immune effector functions completely abolished
Wilkinson, I. C., Anderson, S., Fry, J. W., Julien, L. A., Neville, D. C. A., Qureshi, O. S., Watts, G., & Hale, G. (2021) · PLoS ONE · doi:10.1371/journal.pone.0260954 · Cited by 134
“This became particularly evident with the disastrous results of administering the IgG4 anti-CD28 antibody TGN1412 [5, 39].”
Cytokines: The Good, the Bad, and the Deadly
Ramani, T., Auletta, C. S., Weinstock, D., Mounho-Zamora, B., Ryan, P. C., Salcedo, T. W., & Bannish, G. (2015) · International Journal of Toxicology · doi:10.1177/1091581815584918 · Cited by 127
Fcγ receptors and immunomodulatory antibodies in cancer
Gálvez‐Cancino, F., Simpson, A. P., Costoya, C., Matos, I. G., Qian, D., Peggs, K. S., Litchfield, K., & Quezada, S. A. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00637-8 · Cited by 104
Retargeting T Cells to GD2 Pentasaccharide on Human Tumors Using Bispecific Humanized Antibody
Xu, H., Cheng, M., Guo, H., Chen, Y., Huse, M., & Cheung, N.-K. V. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0230-t · Cited by 92
“Cytokine storm is known to be FcgR-dependent, with severity mainly correlating with IL2 and/or IL6 release (14, 32, 33).”
BackgroundInfluentialVessillier, S., Eastwood, D., Fox, B. J., Sathish, J. G., Sethu, S., Dougall, T., Thorpe, S. J., Thorpe, R., & Stebbings, R. (2015) · Journal of Immunological Methods · doi:10.1016/j.jim.2015.04.020 · Cited by 76
“, 2014); high density pre-culture (HDC) of PBMC followed by incubation with AQ therapeutic mAbs (R mer et al., 2011; Bartholomaeus et al., 2014); WB or diluted WB incubated with AQ therapeutic mAbs (Wolf et al.”
BackgroundMethodInfluentialWang, L., Hoseini, S. S., Xu, H., Ponomarev, V., & Cheung, N. V. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0121 · Cited by 72
“A deeper understanding of the role of residual Fc functions, whether in ADCC or in CDC, should avoid unexpected acute or late effects in the clinical development of BsAbs, a requisite consideration since the lesson of TGN1412 (46, 47).”
BackgroundIgG regulation through FcRn blocking: A novel mechanism for the treatment of myasthenia gravis
Wolfe, G. I., Ward, E. S., de Haard, H., Ulrichts, P., Mozaffar, T., Pasnoor, M., & Vidarsson, G. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.118074 · Cited by 70
“…has been shown to interact with Fc γ receptors (as was demonstrated to be the cause of the cytokine release syndrome for the superagonistic anti-CD28 antibody TGN1412), the headaches observed with IgG4 monoclonal antibodies can be hypothesized to be associated with immune effector functions [111].”
The many faces of FcγRI: implications for therapeutic antibody function
Swisher, J. F. A., & Feldman, G. M. (2015) · Immunological Reviews · doi:10.1111/imr.12334 · Cited by 68
“Fc clustering by FccR is now believed to have played a role in the overwhelming cytokine storm induced by this potential therapeutic (134, 135).”
BackgroundUpregulation of FcγRIIb on monocytes is necessary to promote the superagonist activity of TGN1412
Hussain, K., Hargreaves, C. E., Roghanian, A., Oldham, R. J., Chan, H. T. C., Mockridge, C. I., Chowdhury, F., Frendéus, B., Harper, K., Strefford, J. C., et al. (2014) · Blood · doi:10.1182/blood-2014-08-593061 · Cited by 61
“Expression of FcgRIIb is increased on HD precultured monocytes The finding that the TGN1412 response could be restored by monocytes as well as B cells and that this response was blocked by antiFcgRIIb was unexpected because FcgRIIb is expressed on only a fraction of monocytes and at very low density.19 We then compare…”
BackgroundResultInfluentialGrimaldi, C. M., Finco, D., Fort, M. M., Gliddon, D., Harper, K., Helms, W. S., Mitchell, J. A., O’Lone, R. B., Parish, S. T., Piché, M.-S., et al. (2016) · Cytokine · doi:10.1016/j.cyto.2016.06.006 · Cited by 55
Development and Characterization of Monoclonal Antibodies Specific for Mouse and Human Fcγ Receptors
Tutt, A. L., James, S., Laversin, S. A., Tipton, T. R. W., Ashton‐Key, M., French, R. R., Hussain, K., Vaughan, A. T., Dou, L., Earley, A., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402988 · Cited by 53
“Although initially proposed to be related solely to CD28 expression on a particular subset of T cells and independent of hFcgR expression, it is now evident that hFcgR and in particular hFcgRIIB is critical for this response, at least in predictive in vitro assays (53, 54) and our own observations (55).”
BackgroundThe rise and fall of the CD 28 superagonist TGN 1412 and its return as TAB 08: a personal account
Hünig, T. (2016) · The FEBS Journal · doi:10.1111/febs.13754 · Cited by 47
Self-citationRoghanian, A., Stopforth, R. J., Dahal, L. N., & Cragg, M. S. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.2mir0917-354r · Cited by 46
TGN1412 Induces Lymphopenia and Human Cytokine Release in a Humanized Mouse Model
Weißmüller, S., Kronhart, S., Kreuz, D., Schnierle, B. S., Kalinke, U., Kirberg, J., Hanschmann, K.-M. O., & Waibler, Z. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149093 · Cited by 45
Self-citationSystematic analysis of Fc mutations designed to reduce binding to Fc-gamma receptors
Hale, G., Vos, J. D., Davy, A. D., Sandra, K., & Wilkinson, I. (2024) · mAbs · doi:10.1080/19420862.2024.2402701 · Cited by 44
“22,23 Meanwhile, variant antibodies had been developed with Fc regions mutated to reduce binding to Fc gamma receptors and also to C1q.”
Wilkinson, I. C., & Hale, G. (2022) · mAbs · doi:10.1080/19420862.2022.2123299 · Cited by 41
“Trends in their usage are shown in Figure 12, where it is notable that wild-type or stabilized IgG4 continues to be widely used despite the catastrophic side effects attributable to unwanted FcγR binding which were seen with the superagonistic CD28 antibody TGN1412 in 2006.(35)”
BackgroundAnimal extrapolation in preclinical studies: An analysis of the tragic case of TGN1412
Lemoine, M. (2016) · Studies in History and Philosophy of Science Part C Studies in History and Philosophy of Biological and Biomedical Sciences · doi:10.1016/j.shpsc.2016.12.004 · Cited by 28
Hussain, K., Hargreaves, C. E., Rowley, T. F., Sopp, J. M., Latham, K. V., Bhatta, P., Sherington, J., Cutler, R. M., Humphreys, D. P., Glennie, M. J., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00390 · Cited by 28
Role of FcγRs in Antibody-Based Cancer Therapy
Graziano, R. F., & Engelhardt, J. (2019) · Current topics in microbiology and immunology · doi:10.1007/82_2019_150 · Cited by 25
Ryan, J. M., Wasser, J. S., Adler, A. J., & Vella, A. T. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1152256 · Cited by 24
“(depicted in Figure 1B, in this case using CD137 as a representative example).[163,164] Another school of thought points”
MethodVessillier, S., Fort, M. M., O’Donnell, L. M., Hinton, H. J., Nadwodny, K. L., Piccotti, J. R., Rigsby, P., Staflin, K., Stebbings, R., Mekala, D. J., et al. (2020) · Cytokine X · doi:10.1016/j.cytox.2020.100042 · Cited by 22
“during high density pre-culture of PBMC in the presence of CD32-expressing cells [35,36].”
BackgroundRegulation of Monoclonal Antibody Immunotherapy by FcγRIIB
Stopforth, R. J., Cleary, K. L. S., & Cragg, M. S. (2016) · Journal of Clinical Immunology · doi:10.1007/s10875-016-0247-8 · Cited by 19
“in particular CD32B, can provide a crosslinking function (in trans) that is required to elicit potent cytokine release from TGN1412-opsonised T lymphocytes [36].”
BackgroundHuman Fcγ receptors compete for TGN1412 binding that determines the antibody's effector function
Dudek, S., Weißmüller, S., Anzaghe, M., Miller, L., Sterr, S., Hoffmann, K., Hengel, H., & Waibler, Z. (2019) · European Journal of Immunology · doi:10.1002/eji.201847924 · Cited by 11
Self-citationIyer, R. F., Edwards, D. M., Kolb, P., Raué, H.-P., Nelson, C. A., Epperson, M. L., Slifka, M. K., Nolz, J. C., Hengel, H., Fremont, D. H., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010783 · Cited by 10
Self-citationFinding the Right Heavy Chains for Immunostimulatory Antibodies
Boulard, P., Gouilleux‐Gruart, V., & Watier, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810367 · Cited by 9
Lux, A., & Nimmerjahn, F. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.12.010 · Cited by 8
“…level of crosslinking may result in severe side effects, such as an uncontrolled release of proinflammatory cytokines, which, according to recent data may at least in part explain the severe side effects in a clinical trial with a superagonistic CD28-specific antibody (Bartholomaeus et al., 2014).”
BackgroundHighly sensitive in vitro cytokine release assay incorporating high-density preculture
Ito, S., Miwa, K., Hattori, C., Aida, T., Tsuchiya, Y., & Mori, K. (2021) · Journal of Immunotoxicology · doi:10.1080/1547691x.2021.1984617 · Cited by 6
“Culture conditions for the HDC were based on previous publications (R€omer et al. 2011; Bartholomaeus et al. 2014; Hussain et al. 2015, 2019).”
BackgroundMethodAntibody induced CD4 down-modulation of T cells is site-specifically mediated by CD64+ cells
Vogel, S., Grabski, E., Buschjäger, D., Klawonn, F., Döring, M., Wang, J., Fletcher, E. A. K., Bechmann, I., Witte, T., Ďurišin, M., et al. (2015) · Scientific Reports · doi:10.1038/srep18308 · Cited by 6
Self-citationMadsen, N. H., Gad, M., & Larsen, J. (2022) · Journal of Immunological Methods · doi:10.1016/j.jim.2022.113231 · Cited by 4
Szikszai, T., Lasitschka, F., Giese, T., Greulich, M., Lee, Y.-S., Ilse, J., Schiessling, S., Leowardi, C., Al‐Saeedi, M., Winter, J., et al. (2015) · Journal of Immunological Methods · doi:10.1016/j.jim.2014.12.014 · Cited by 3
Harada, A., Shioda, A., Ikuno, T., Iwata, Y., Shiraiwa, H., Wakabayashi, T., Sano, Y., & Mishima, M. (2020) · Toxicology in Vitro · doi:10.1016/j.tiv.2020.104841 · Cited by 2
CD28 Superagonist Shock and Blockage of Motogenic T Cell Cascade
Sundqvist, K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.670864 · Cited by 2
MacLeod, E., Rajagopal, D., & Vessillier, S. (2023) · Journal of Visualized Experiments · doi:10.3791/65087 · Cited by 1
Quelles chaînes lourdes d’immunoglobulines pour quels anticorps d’immunostimulation ?
Dumet, C., & Watier, H. (2019) · médecine/sciences · doi:10.1051/medsci/2019241
MacLeod, E., Rajagopal, D., & Vessillier, S. (2023) · doi:10.3791/65087-v
Role of FcγRs in anti-OX40 based immunotherapies
Costoya, C. (2023) · UCL Discovery (University College London)
Manipulating immune checkpoint signalling pathways with antibodies
Paluch, C. (2019) · Oxford University Research Archive (ORA) (University of Oxford) · doi:10.5287/ora-14av0ogv8
Hofstetter, M., Volta, L. G., Koch, C., Rey, M. G., Maurer, M., Gonullu, N. G., Pellegrino, C. E., Gobbi, C., Schneiter, F., Manfredi, F., et al. (2026) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0672
“This activation was driven by cross-linking of CD28 receptors on T cells, which might have been facilitated in vivo by Fc γ receptor–bearing accessory cells, immobilizing the antibody via its Fc region (45, 46).”
Fc-engineering for improved cancer immunotherapy
Borgman, E., Gall, C. M. L., Ploegh, H. L., & Pishesha, N. (2026) · Biochemical Society Transactions · doi:10.1042/bst20250554
Metadata
- Authors
- Bartholomaeus, P., Semmler, L. Y., Bukur, T., Boisguerin, V., Römer, P. S., Tabares, P., Chuvpilo, S., Tyrsin, D. Y., Matskevich, A., Hengel, H., Castle, J., Hünig, T., & Kalinke, U.
- Affiliations
- Institute for Experimental Infection Research, TWINCORE, Center for Experimental and Clinical Infection Research, Helmholtz Centre for Infection Research, Braunschweig, and Hannover Medical School , 30625 Hannover,
- Medizinische Hochschule Hannover (DE)
- Johannes Gutenberg University Mainz (DE)
- Translational Oncology at the University Medical Center Mainz, Johannes Gutenberg University of Mainz , 55131 Mainz,
- University of Würzburg (DE)
- TheraMAB , 121069 Moscow,
- University of Freiburg (DE)
- Corresponding author
- Kalinke, Ulrich
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-03-01
- Volume
- 192
- Issue
- 5
- Pages
- 2091-2098
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2124259702
- Cited by
- 40
- References
- 39
- Citations by year
- 2026: 2 · 2024: 1 · 2023: 2 · 2022: 4 · 2021: 4 · 2020: 2 · 2019: 5 · 2018: 3 · 2016: 6 · 2015: 8 · 2014: 3
- FWCI
- 4.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of California, Santa Cruz
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Keywords
- TGN1412, anti-CD28 monoclonal antibody, cytokine release syndrome, CD32, T cell activation, T cell-B cell interaction, IgG4, in vitro toxicity testing, T cell transcriptome
- MeSH terms
- Female, Gene Expression Regulation, Humans, Immunoglobulin G, Immunoglobulin Fc Fragments, Male, Cytokines, Receptors, IgG, Gene Expression Profiling, Transcriptome, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.